Arzerra (ofatumumab)
Drugs for Cancer : Drugs for Cancer
  • Chronic Lymphocytic Leukemia:
    Duration: 12 Month(s)
    Specialist Required: Yes
    Documented Diagnosis: Yes
    Medical Test Required: No
    Specialist Type(s): 1 of Hematologist;Oncologist
    Reauthorization Required: No
    Duration of Reauthorization: N/A
    Drug Policy Based On: Payer Specific
    Concomitant Therapy Requirement: 1 of chlorambucil;fludarabine and cyclophosphamide
    Diagnosis Types: 1 of CLL for relapsed/refractory disease;extended use in complete/partial response after >= 2 lines of therapy for recurrent/progressive CLL;first line in combination with chlorambucil where fludarabine therapy is inappropriate;for the treatment of patients with CLL refractory to fludarabine and alemtuzumab

  • Prior Authorization: Chronic Lymphocytic Leukemia:
    Documented Diagnosis: Yes
    Duration: 12 Month(s)